Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.

• Status: Completed
• Trial end date: 2020-03-06

Summary

The purpose of this study is to assess the safety, tolerability, biomarker and cognitive efficacy of investigational products in subjects who are known to have an Alzheimer's disease-causing mutation by determining if treatment with the study drug slows the rate of progression of cognitive impairment and improves disease-related biomarkers.

This is an analysis study for an MPRP: DIAN-TU-001 Master NCT01760005

• Phase: Phase 2/Phase 3

Details

• Lead Sponsor: Washington University School of Medicine
• Collaborators: Accelerating Medicines Partnership (AMP); Alzheimer's Association; Avid Radiopharmaceuticals; Eli Lilly and Company; Hoffmann-La Roche; National Institute on Aging (NIA)
• Treatments: Antibodies, Monoclonal